Cargando…
Drug–Target Kinetics in Drug Discovery
[Image: see text] The development of therapies for the treatment of neurological cancer faces a number of major challenges including the synthesis of small molecule agents that can penetrate the blood-brain barrier (BBB). Given the likelihood that in many cases drug exposure will be lower in the CNS...
Autor principal: | Tonge, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2017
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767540/ https://www.ncbi.nlm.nih.gov/pubmed/28640596 http://dx.doi.org/10.1021/acschemneuro.7b00185 |
Ejemplares similares
-
Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis
por: Kinnings, Sarah L., et al.
Publicado: (2009) -
SAR by kinetics for drug discovery in protein misfolding diseases
por: Chia, Sean, et al.
Publicado: (2018) -
Correlating drug–target kinetics and in vivo pharmacodynamics: long residence time inhibitors of the FabI enoyl-ACP reductase
por: Daryaee, Fereidoon, et al.
Publicado: (2016) -
Astrocytes as targets for drug discovery
por: Gorshkov, Kirill, et al.
Publicado: (2018) -
Moving targets in drug discovery
por: Zdrazil, Barbara, et al.
Publicado: (2020)